Artículos de revistas
Factors Affecting 223ra Therapy: Clinical Experience After 532 Cycles From A Single Institution
Registro en:
European Journal Of Nuclear Medicine And Molecular Imaging. Springer Berlin, v. 43, n. 1, p. 8 - 20, 2016.
16197070
10.1007/s00259-015-3185-4
2-s2.0-84951906696
Institución
Resumen
Purpose: The aim of this study was to identify baseline features that predict outcome in 223Ra therapy. Methods: We retrospectively reviewed 110 patients with metastatic castration-resistant prostate cancer treated with 223Ra. End points were overall survival (OS), progression-free survival (PFS), bone event-free survival (BeFS), and bone marrow failure (BMF). The following parameters were evaluated prior to the first 223Ra cycle: serum levels of hemoglobin (Hb), prostate-specific antigen (PSA), alkaline phosphatase (ALP), Eastern Cooperative Oncology Group (ECOG) status, pain score, use of chemotherapy, and external beam radiation therapy (EBRT). During/after 223Ra we evaluated: the total number of radium cycles (RaTot), the PSA doubling time (PSADT), and the use of chemotherapy, EBRT, abiraterone, and enzalutamide. Results: A significant reduction of ALP (p < 0.001) and pain score (p = 0.041) occurred throughout the 223 Ra cycles. The risk of progression was associated with declining ECOG status [hazard ratio (HR) = 3.79; p < 0.001] and decrease in PSADT (HR = 8.22; p < 0.001). RaTot, ALP, initial ECOG status, initial pain score, and use of abiraterone were associated with OS (p ≤ 0.008), PFS (p ≤ 0.003), and BeFS (p ≤ 0.020). RaTot, ALP, initial ECOG status, and initial pain score were significantly associated with BMF (p ≤ 0.001) as well as Hb (p < 0.001) and EBRT (p = 0.009). On multivariable analysis, only RaTot and abiraterone remained significantly associated with OS (p < 0.001; p = 0.033, respectively), PFS (p < 0.001; p = 0.041, respectively), and BeFS (p < 0.001; p = 0.019, respectively). Additionally, RaTot (p = 0.027) and EBRT (p = 0.013) remained significantly associated with BMF. Conclusion: Concomitant use of abiraterone and 223Ra seems to have a beneficial effect, while the EBRT may increase the risk of BMF. © 2015, Springer-Verlag Berlin Heidelberg. 43 1 8 20 Hoskin, P., Sartor, O., O’Sullivan, J.M., Johannessen, D.C., Helle, S.I., Logue, J., Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial (2014) Lancet Oncol, 15, pp. 1397-1406. , COI: 1:CAS:528:DC%2BC2cXhsl2hu7fE, PID: 25439694 Parker, C., Nilsson, S., Heinrich, D., Helle, S.I., O’Sullivan, J.M., Fosså, S.D., Alpha emitter radium-223 and survival in metastatic prostate cancer (2013) N Engl J Med, 369, pp. 213-223. , COI: 1:CAS:528:DC%2BC3sXhtFKls77M, PID: 23863050 Nilsson, S., Franzén, L., Parker, C., Tyrrell, C., Blom, R., Tennvall, J., Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases (2013) Clin Genitourin Cancer, 11, pp. 20-26. , PID: 23021204 Fizazi, K., Massard, C., Smith, M., Rader, M., Brown, J., Milecki, P., Bone-related parameters are the main prognostic factors for overall survival in men with bone metastases from castration-resistant prostate cancer (2015) Eur Urol, 68, pp. 42-50. , PID: 25449207 Jadvar, H., Challa, S., Quinn, D.I., Conti, P.S., One-year postapproval clinical experience with radium-223 dichloride in patients with metastatic castrate-resistant prostate cancer (2015) Cancer Biother Radiopharm, 30, pp. 195-199. , COI: 1:CAS:528:DC%2BC2MXhtVKkurvK, PID: 25746633 Kelloff, G.J., Coffey, D.S., Chabner, B.A., Dicker, A.P., Guyton, K.Z., Nisen, P.D., Prostate-specific antigen doubling time as a surrogate marker for evaluation of oncologic drugs to treat prostate cancer (2004) Clin Cancer Res, 10, pp. 3927-3933. , COI: 1:CAS:528:DC%2BD2cXksVKntLg%3D, PID: 15173102 Humm, J.L., Sartor, O., Parker, C., Bruland, O.S., Macklis, R., Radium-223 in the treatment of osteoblastic metastases: a critical clinical review (2015) Int J Radiat Oncol Biol Phys, 91, pp. 898-906. , PID: 25832684 Den, R.B., Doyle, L.A., Knudsen, K.E., Practical guide to the use of radium 223 dichloride (2014) Can J Urol, 21, pp. 70-76. , PID: 24775727 Nilsson, S., Larsen, R.H., Fosså, S.D., Balteskard, L., Borch, K.W., Westlin, J.E., First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases (2005) Clin Cancer Res, 11, pp. 4451-4459. , COI: 1:CAS:528:DC%2BD2MXltFeksrc%3D, PID: 15958630 de Bono, J.S., Logothetis, C.J., Molina, A., Fizazi, K., North, S., Chu, L., Abiraterone and increased survival in metastatic prostate cancer (2011) N Engl J Med, 364, pp. 1995-2005. , PID: 21612468 Beckett, R.D., Rodeffer, K.M., Snodgrass, R., Abiraterone for the treatment of metastatic castrate-resistant prostate cancer (2012) Ann Pharmacother, 46, pp. 1016-1024. , PID: 22714819 Fizazi, K., Scher, H.I., Molina, A., Logothetis, C.J., Chi, K.N., Jones, R.J., Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study (2012) Lancet Oncol, 13, pp. 983-992. , COI: 1:CAS:528:DC%2BC38XhsVCjsbjK, PID: 22995653 Hingorani, M., Dixit, S., Pugazhenthi, P., Hawkyard, S., Robertson, A., Khafagy, R., Can palliative radiotherapy influence prostate-specific antigen response in patients with castrate-resistant prostate cancer treated with systemic therapy (chemotherapy or abiraterone)?-a report of three cases (2015) Cancer Biol Med, 12, pp. 60-63. , PID: 25859413 Graff, J.N., Gordon, M.J., Beer, T.M., Safety and effectiveness of enzalutamide in men with metastatic, castration-resistant prostate cancer (2015) Expert Opin Pharmacother, 16, pp. 749-754. , COI: 1:CAS:528:DC%2BC2MXktlCisrk%3D, PID: 25687355 Tan, P.S., Haaland, B., Montero, A.J., Kyriakopoulos, C.E., Lopes, G., Hormonal therapeutics enzalutamide and abiraterone acetate in the treatment of metastatic castration-resistant prostate cancer (mCRPC) post-docetaxel-an indirect comparison (2014) Clin Med Insights Oncol, 8, pp. 29-36. , COI: 1:CAS:528:DC%2BC2cXhs12gs7%2FF, PID: 24678245 Yeku, O., Slovin, S.F., Metabolism and pharmacokinetics of radium-223 in prostate cancer (2015) Expert Opin Drug Metab Toxicol, 11, pp. 843-849. , COI: 1:CAS:528:DC%2BC2MXotVeks7g%3D, PID: 25740232 Geenen, R.W., Delaere, K.P., van Wersch, J.W., Haematological variables in prostatic carcinoma patients (1996) Acta Urol Belg, 64, pp. 21-26. , COI: 1:STN:280:DyaK2s7gt1alug%3D%3D, PID: 8946777 Etchebehere, E., Araujo, J.C., Milton, D., Fox, P., Swanston, N., Macapinlac, H., Skeletal tumor burden on baseline 18F-fluoride PET/CT to predict bone marrow failure after radium-223 (2015) J Clin Oncol, 33, p. 11012